Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

NCT03770000 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

T Cell Lymphoma

Interventions

DRUG: Tenalisib
DRUG: Romidepsin

Sponsor

Rhizen Pharmaceuticals SA